查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011248

兽用疫苗市场：按产品类型、目标动物、给药途径、疾病类型和分销管道分類的全球市场预测，2026-2032年

Veterinary Vaccines Market by Product Type, Animal Type, Route Of Administration, Disease Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，兽用疫苗市场价值将达到 150.5 亿美元，到 2026 年将成长至 160.4 亿美元，到 2032 年将达到 241.5 亿美元，复合年增长率为 6.99%。

主要市场统计数据
基准年 2025 150.5亿美元
预计年份：2026年 160.4亿美元
预测年份 2032 241.5亿美元
复合年增长率 (%) 6.99%

一份引人入胜且全面的介绍，概述了兽用疫苗的现状、主要需求驱动因素、技术变革以及全球相关人员的战略重点。

兽用疫苗领域涉及生物技术、动物福利和全球贸易动态的交汇点，牵涉到从研究机构到兽医诊所的众多相关人员。本导言概述了影响短期决策的核心主题：抗原设计和递送方面的科学创新、物种间疾病负担的波动以及依赖低温运输的生技药品的实际操作。透过说明观点和商业性观点，读者将获得将实验室进展转化为临床成果和供应链执行的实用指南。

快速的技术创新、动物健康领域的模式转移、不断发展的法规结构以及新的经营模式正在重塑兽用疫苗的格局和价值链。

兽用疫苗领域正经历一场变革，背后是多种因素的复杂相互作用。分子生物学和载体工程的进步正在加速开发新一代疫苗平台，例如次单元、重组疫苗和病毒载体疫苗，从而拓展了控制复杂病毒和寄生虫疾病的工具库。同时，佐剂科学和製剂技术的进步使得疫苗产品更加稳定，剂量也得以降低，这影响着疫苗的物流、给药方案的製定以及兽医的采纳。

评估美国于 2025 年实施的进口关税对进口、供应连续性、价格趋势和下游兽医服务的累积营运、成本和贸易影响。

2025年实施的贸易措施和关税调整为兽用疫苗生产中生物製药和辅助材料的全球供应链带来了新的摩擦。这些措施改变了进口原材料的成本计算方式，特别是试剂、特殊黏合剂、一次性组件以及此前关税负担低且跨境流通的成品。为此，生产商和经销商正在重新审视筹资策略，加快供应商认证计划，并探索关键供应链的地域多角化，以降低贸易相关成本波动带来的风险。

详细的细分洞察揭示了产品类型、动物类别、给药途径、目标疾病和分销管道如何全面影响临床引入和商业策略。

深入了解市场区隔对于使产品策略与临床需求和商业性可行性相符至关重要。按产品类型划分，该领域包括灭活疫苗、减毒活病毒疫苗、次单元疫苗和重组疫苗以及病毒载体疫苗，每种疫苗都有其自身的研发计划、安全性以及低温运输的依赖性，这些因素都会影响市场进入的选择。依动物种类划分，市场分为伴侣动物和牲畜。在伴侣动物领域，猫和狗是主要目标市场，重点在于便利性、安全性和饲主主导的购买行为。在牲畜领域，牛、家禽、羊和猪的群体疾病管制是首要任务，规模经济和监管监督会影响疫苗的普及趋势。

区域分析重点在于美洲、欧洲、中东和非洲以及亚太地区的差异化需求驱动因素、监管细微差别、製造地和分销挑战。

地理因素对疫苗研发重点、监管策略和分销方式有显着影响。在美洲，完善的兽医基础设施、较高的宠物饲养率和成熟的商业管道正在推动高级产品和数位化分销模式的快速普及。该地区的生产商日益重视生命週期数据和上市后安全性监测，同时利用先进的低温运输物流来支援复杂的生物製药。

分析主要研发公司、生技药品製造商、契约製造製造商、经销商和服务供应商之间的竞争与合作趋势，有助于制定策略定位和创新策略。

兽用疫苗产业的竞争动态是由那些兼具研发深度、生产规模和分销网络的企业所塑造。一条策略轴线将那些大力投资于专有平台技术和产品线多样性的企业与那些专注于特定适应症或合约服务（例如填充、包装和低温运输物流）的企业区分开来。伙伴关係和授权协议是弥合能力差距的常用机制。以研发为导向的企业通常与大规模製造商合作以加速市场准入，而区域经销商和临床网路则提供市场渗透能力。

为产业领导者提供具有重大影响的策略建议，以加速疫苗创新、增强供应韧性、优化市场进入并提高所有管道的商业性可行性。

领导者应优先采取一系列切实可行且影响深远的措施，以应对当前环境并抓住机会。首先，投资于平台的多功能性和模组化生产能力，使其能够快速重新配置以适应不同的抗原类型和剂型。这将缩短临床试验时间并支援区域生产策略。其次，加强供应商多元化和合格计划，以降低关税相关的采购风险。这包括与合格的契约製造以及本地灌装和包装合作伙伴建立合作关係，以确保即使在贸易政策波动的情况下也能保持业务的连续性。

为了确保分析的有效性和可重复性，我们采用了一种稳健的混合调查方法，结合了与主要相关人员的对话、二手文献的整合以及严格的数据三角测量。

本研究采用混合方法，旨在兼顾深度与效度。主要研究包括对科学领导者、监管专家、製造企业高管和分销合作伙伴进行结构化访谈，以确定实际限制因素和前瞻性优先事项。这些定性见解指南了后续的针对性研究，以确定主题优先事项并阐明技术依赖性和商业性考虑。除主要资料外，广泛整合同侪审查文献、监管指导文件和行业白皮书，为平台和疾病特异性分析提供了技术基础。

简要概述了高阶决策者在应对不断变化的动物疫苗生态系统时应关注的策略要点、未解决的问题和短期优先事项。

本分析整合了技术进步、监管政策变化、市场区隔现状、区域趋势以及贸易政策变动对动物疫苗产业的策略影响。主要结论包括：需要在创新与业务永续营运之间取得平衡；区域生产和分销灵活性具有战略价值；以及基于市场细分的产品策略至关重要，这些策略应反映伴侣动物市场和牲畜市场的差异。总体而言，这些发现表明，对平台和供应链多元化以及监管参与进行战术性投资，可以在市场进入和临床应用方面带来显着回报。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 兽用疫苗市场：依产品类型划分

  • 灭活疫苗
  • 减毒活病毒疫苗
  • 次单元疫苗和重组疫苗
  • 病毒载体疫苗

第九章 兽用疫苗市场：依动物类型划分

  • 伴侣动物
    • 猫
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 猪

第十章 兽用疫苗市场：依给药途径划分

  • 口服
  • 肠外
  • 外用

第十一章 兽用疫苗市场：依疾病类型划分

  • 细菌感染疾病
    • 梭状芽孢桿菌
    • 大肠桿菌
    • 钩端螺旋体病
    • 巴斯德氏菌
  • 霉菌感染疾病
  • 寄生虫感染疾病
    • 体外寄生虫
    • 体内寄生虫
  • 病毒感染疾病
    • 禽流感病毒
    • 牛病毒性腹泻病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 猪繁殖与呼吸综合症病毒（PRRSV）
    • 狂犬病毒

第十二章 兽用疫苗市场：依通路划分

  • 网路药房
  • 零售药房
  • 动物医院

第十三章 兽用疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 兽用疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 兽用疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国兽用疫苗市场

第十七章：中国兽用疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • SAN Group Biotech Germany GmbH
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-4316E4E89380

The Veterinary Vaccines Market was valued at USD 15.05 billion in 2025 and is projected to grow to USD 16.04 billion in 2026, with a CAGR of 6.99%, reaching USD 24.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.05 billion
Estimated Year [2026] USD 16.04 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 6.99%

A compelling, comprehensive introduction that frames the current state of veterinary vaccines, key demand drivers, technological inflections, and strategic priorities for stakeholders globally

The veterinary vaccines domain sits at the intersection of biotechnology, animal welfare, and global trade dynamics, with stakeholders ranging from research laboratories to frontline veterinary practices. This introduction frames the core themes that drive near-term decision-making: scientific innovation in antigen design and delivery, shifting disease burdens across species, and the operational realities of cold-chain dependent biologics. By grounding the narrative in both scientific and commercial perspectives, readers gain a practical orientation that links laboratory advances to clinic-level outcomes and supply-chain execution.

In addition, the introduction outlines the primary levers that influence program viability and adoption. These include evolving regulatory expectations for immunogenicity and safety, the economics of companion animal versus livestock interventions, and the role of distribution networks in ensuring timely access. Taken together, the early section establishes the analytical lens used throughout the study, emphasizing actionable insights over abstract trends and setting expectations for how subsequent analysis will translate into strategic choices for R&D, manufacturing, and commercial teams.

How rapid technological innovation, shifting animal health paradigms, evolving regulatory frameworks, and new commercial models are together reshaping the veterinary vaccines landscape and value chains

The landscape of veterinary vaccines is undergoing a period of transformative change driven by multiple, interlocking forces. Advances in molecular biology and vector engineering have accelerated the development of next-generation platforms such as subunit, recombinant, and viral vector approaches, expanding the toolkit available to control complex viral and parasitic diseases. Concurrently, improvements in adjuvant science and formulation technologies are enabling more stable products with reduced dosing requirements, which in turn affect logistics, dosing regimens, and uptake among practitioners.

At the same time, regulatory authorities are adapting frameworks to accommodate novel modalities and expedited pathways for high-priority animal health threats. This regulatory evolution is producing both opportunities and complexities: faster pathways for certain constructs are balanced by heightened expectations for post-market surveillance and batch-release data. Commercially, digital veterinary services and online distribution channels are reshaping how vaccines reach end users, with telemedicine and e-commerce altering demand patterns for companion animal vaccines and creating alternate routes to market. Finally, growing emphasis on One Health perspectives is aligning public and private priorities around zoonotic risk mitigation, which increases collaboration across human and animal health domains and elevates investment in vaccines that reduce cross-species transmission.

Assessing the cumulative operational, cost and trade impacts of the United States tariffs enacted in 2025 on imports, supply continuity, pricing dynamics, and downstream veterinary services

The imposition of trade measures and tariff adjustments in 2025 introduced new friction into global supply chains for biologics and ancillary materials used in veterinary vaccine manufacture. These measures have changed the calculus for imported inputs, particularly reagents, specialty adhesives, single-use components, and finished-dose products that historically moved across borders with lower tariff exposure. In response, manufacturers and distributors have reassessed sourcing strategies, accelerated supplier qualification programs, and explored regionalization of critical supply lines to reduce vulnerability to trade-related cost volatility.

Operationally, the tariffs have amplified the importance of local manufacturing capacity and warehousing agility. Firms with pre-existing regional production hubs were able to mitigate exposure more effectively, whereas organizations reliant on long-haul imports faced longer lead times and higher landed costs. The policy environment has also encouraged contractual renegotiations and greater use of hedging strategies for currency and procurement. For clinical and commercial teams, the practical outcome has been a renewed focus on prioritizing product portfolios for geographies where supply reliability and cost predictability can be maintained, while exploring partnerships and licensing that allow for localized fill-finish and distribution to preserve market access under changing trade regimes.

Deep segmentation insights revealing how product types, animal categories, administration routes, disease targets, and distribution channels collectively inform clinical adoption and commercial strategies

A nuanced understanding of market segmentation is essential to align product strategy with clinical need and commercial feasibility. Based on product type, the domain includes Inactivated Vaccines, Live Attenuated Vaccines, Subunit & Recombinant Vaccines, and Viral Vector Vaccines, each presenting distinct development timelines, safety profiles, and cold-chain dependencies that influence go-to-market choices. When examined by animal type, the market divides between Companion Animals and Livestock Animals; companion animal work largely concentrates on Cats and Dogs with emphasis on convenience, safety and owner-driven purchasing behavior, while livestock efforts prioritize herd-level disease control across Cattle, Poultry, Sheep, and Swine with scale efficiencies and regulatory oversight shaping adoption dynamics.

Route of administration introduces further differentiation, with Oral, Parenteral, and Topical delivery pathways offering varying trade-offs between ease of administration, immune response quality, and formulation complexity. Disease-type considerations add another strategic layer: vaccines targeting Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections must be designed and communicated differently. Bacterial indications encompass Clostridial illness, E. coli syndromes, Leptospirosis, and Pasteurella, each requiring targeted antigens and often adjuvant optimization. Parasitic disease work addresses both Ectoparasites and Endoparasites, where vaccine-induced protection must be balanced against environmental and management controls. Viral vaccine targets range from Avian Influenza Virus to Bovine Viral Diarrhea Virus, Foot-and-Mouth Disease Virus, Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus, and Rabies Virus, each presenting unique immunological challenges and regulatory considerations. Finally, distribution channel dynamics across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics shape commercial execution: direct clinic distribution favors practitioner influence and cold-chain stewardship, retail pharmacies offer consumer convenience, and online pharmacies create new purchasing pathways that require digital logistics and trust-building for vaccine products.

Region-focused intelligence highlighting differentiated demand drivers, regulatory nuances, manufacturing hubs, and distribution challenges across the Americas, EMEA, and Asia-Pacific regions

Geographic dynamics materially influence vaccine development priorities, regulatory strategy, and distribution approaches. In the Americas, strong veterinary infrastructure, high companion animal ownership rates, and established commercial channels favor rapid adoption of premium products and digital distribution models. Producers in this region increasingly emphasize lifecycle data and post-market safety monitoring while leveraging sophisticated cold-chain logistics to support complex biologics.

Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with wide heterogeneity in manufacturing capacity and purchasing power. This region demands flexible strategies that accommodate stringent regulatory expectations in some markets alongside capacity-building and cost-sensitive models in others. Meanwhile, Asia-Pacific reflects a mix of large-scale livestock production systems, emergent manufacturing hubs, and rising companion animal ownership that together create both high-volume opportunities and the need for scalable, locally adapted supply solutions. Across all regions, local regulatory pathways, import controls, and distribution infrastructures remain decisive factors in the commercial planning and rollout of new veterinary vaccine products.

Competitive and collaborative behavior analysis among leading developers, biologics formulators, contract manufacturers, distributors, and service providers shaping strategic positioning and innovation

Competitive dynamics in the veterinary vaccines space are shaped by companies that combine R&D depth, manufacturing scale, and distribution reach. One strategic axis separates organizations that invest heavily in proprietary platform technologies and pipeline diversity from those that focus on niche indications or contract services such as fill-finish and cold-chain logistics. Partnerships and licensing agreements serve as common mechanisms to bridge capability gaps: research-focused entities frequently collaborate with large-scale manufacturers to expedite commercial access, while regional distributors and clinical networks provide market penetration capacity.

Another important trend is the increasing role of contract manufacturing and specialized biologics service providers that enable smaller innovators to scale without extensive capital investment. These arrangements influence time-to-market and create modular paths to commercialization, especially for subunit and viral vector constructs that demand specific process expertise. From a commercial strategy perspective, companies that align clinical evidence generation with pragmatic distribution models-ensuring appropriate packaging, labeling and cold-chain integrity for end users-tend to achieve better practitioner acceptance and uptake. Finally, collaborative initiatives that address cross-cutting challenges such as cold-chain standardization, regulatory harmonization, and post-market surveillance are becoming more prominent as the industry seeks efficiencies across the value chain.

High-impact strategic recommendations for industry leaders to accelerate vaccine innovation, strengthen supply resilience, optimize market access, and improve commercial execution across channels

Leaders should prioritize a set of pragmatic, high-impact measures to navigate the current environment and capture opportunity. First, invest in platform versatility and modular manufacturing capabilities that allow rapid reconfiguration for different antigen types and dosing formats; this reduces time-to-clinic and supports regional production strategies. Second, strengthen supplier diversification and qualification programs to mitigate tariff-driven sourcing risks, including building relationships with qualified contract manufacturers and local fill-finish partners to preserve continuity under shifting trade policies.

Third, align regulatory strategies early with target market requirements and plan for robust post-market surveillance to satisfy evolving safety expectations; engaging with regulators through parallel consultations can shorten approval pathways for innovative modalities. Fourth, optimize commercial models by tailoring distribution approaches for companion animal versus livestock channels, integrating digital sales and telemedicine where appropriate, and ensuring field-level training for veterinarians and paraprofessionals to improve administration and compliance. Lastly, pursue collaborative initiatives that advance cold-chain resilience and shared data platforms for adverse event monitoring, which will enhance stakeholder confidence and support more rapid adoption of next-generation vaccines.

Robust mixed-methods research methodology combining primary stakeholder engagement, secondary literature synthesis, and rigorous data triangulation to ensure analytical validity and reproducibility

The research underpinning this study follows a mixed-methods approach designed to balance depth and validity. Primary engagement included structured interviews with scientific leaders, regulatory specialists, manufacturing executives, and distribution partners to surface practical constraints and forward-looking priorities. These qualitative inputs informed thematic priorities and guided targeted follow-ups that clarified technical dependencies and commercial considerations. Alongside primary input, an extensive synthesis of peer-reviewed literature, regulatory guidance documents, and industry whitepapers provided the technical foundation for platform-specific and disease-targeted analysis.

Data triangulation was applied to reconcile differences across sources and to validate inferred conclusions. Where possible, technical assertions were corroborated by multiple independent stakeholders to reduce bias. The methodology emphasizes transparency in assumptions and documents analytical boundaries, including the exclusion of speculative forecasts or proprietary financial metrics. In addition, the study incorporated iterative reviews by subject matter experts to ensure that clinical, manufacturing, and commercial interpretations remain robust and aligned with current practice.

Concise synthesis of strategic takeaways, unresolved challenges, and near-term priorities that senior decision-makers should act on to navigate the evolving animal vaccine ecosystem

This analysis synthesizes the strategic implications of technological progress, regulatory evolution, segmentation realities, regional dynamics, and trade policy shifts for the veterinary vaccines sector. Key takeaways include the imperative to balance innovation with operational resilience, the strategic value of regional manufacturing and distribution agility, and the importance of segmentation-informed product strategies that reflect differences between companion animal and livestock markets. Collectively, these insights underscore that tactical investments in platforms, supply chain diversity, and regulatory engagement deliver outsized returns in market access and clinical uptake.

Looking ahead, decision-makers should treat vaccine development not as a linear product project but as an ecosystem challenge that integrates science, manufacturing, regulation, and field execution. By doing so, organizations can better align R&D investments to practical adoption pathways, reduce exposure to external shocks, and accelerate the translation of scientific advances into measurable animal health outcomes. The conclusion therefore reinforces the need for integrated, cross-functional approaches that convert technical advances into durable commercial advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Vaccines Market, by Product Type

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. Subunit & Recombinant Vaccines
  • 8.4. Viral Vector Vaccines

9. Veterinary Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Veterinary Vaccines Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Veterinary Vaccines Market, by Disease Type

  • 11.1. Bacterial Infections
    • 11.1.1. Clostridial
    • 11.1.2. E. Coli
    • 11.1.3. Leptospirosis
    • 11.1.4. Pasteurella
  • 11.2. Fungal Infections
  • 11.3. Parasitic Infections
    • 11.3.1. Ectoparasites
    • 11.3.2. Endoparasites
  • 11.4. Viral Infections
    • 11.4.1. Avian Influenza Virus
    • 11.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 11.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 11.4.4. Newcastle Disease Virus
    • 11.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 11.4.6. Rabies Virus

12. Veterinary Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Veterinary Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Vaccines Market

17. China Veterinary Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Arko Corp.
  • 18.6. Bimeda Biologicals Inc
  • 18.7. Biogenesis Bago S.A.
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Ceva Sante Animale
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Elanco Animal Health Incorporated
  • 18.12. Endovac Animal Health
  • 18.13. Hester Biosciences Limited
  • 18.14. Hipra S.A.
  • 18.15. Huvepharma, Inc.
  • 18.16. Indian Immunologicals Ltd.
  • 18.17. Kemin Industries, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Neogen Corporation
  • 18.20. Pfizer, Inc.
  • 18.21. Phibro Animal Health Corporation
  • 18.22. SAN Group Biotech Germany GmbH
  • 18.23. Seppic by Air Liquide Healthcare
  • 18.24. SK Bioscience
  • 18.25. Vaxxinova
  • 18.26. Virbac S.A.
  • 18.27. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. G7 VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. G7 VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NATO VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)